
Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Bio-Rad Laboratories, Inc. (BIO.B) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NYSE. The stock is currently priced at $379,90, with a market capitalisation of $1,92B and a P/E ratio of 43,89. Over the past 52 weeks, its price has ranged from $244,54 to $384,53. This page covers its latest market performance, valuation, price trends and company information.
$1,92B | |
$375,66 | |
$818,60 | |
$47,00 | |
-- | |
9,00 | |
420,94 | |
43,89 | |
$384,53 | |
$244,54 | |
-- | |
-- |
Bio-Rad Laboratories, Inc. (BIO.B) is trading at $-- in pre-market trading as of 2026-09-15 20:11:00, -- from the previous close of $0,00
Pre-market trading shows how investors are pricing BIO.B before the regular session opens. The current pre-market price is -- the previous close, indicating -- early trading sentiment.
Over the past seven days, Bio-Rad Laboratories, Inc. (BIO.B) moved from $290,00 to $379,90, representing a gain of 31,00% ($89,90).
The stock traded between $289,23 and $384,53 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 232,74 shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 96,7%
BIO.B is currently trading at $379,90, placing it 96,7% of the way from its 52-week low of $244,54 to its 52-week high of $384,53. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 7450 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Bio-Rad Laboratories, Inc. (BIO.B) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.